CMO Tony Hoos leaves SOBI

Head of R&D and Medical Affairs (RDMA) and CMO Tony Hoos is leaving Swedish Orphan Biovitrum AB (SSE:SOBI). Lydia Abad-Franch, head of Medical Affairs & Clinical Science, will become the acting CMO, supported by board member and former Head of RDMA & CMO Anders Ullman, until a permanent successor to Hoos is appointed. 

Peter Halling will succeed Carsten Hellman as president and CEO of allergy immunotherapy company ALK-Abello A/S (CSE:ALK B) no later than Jan.1, 2024. Halling is CEO of Vectura Fertin Pharma Inc...